SINO BIOPHARMACEUTICAL LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.07 HKD | +5.50% |
|
+13.70% | -11.53% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 29.11B 4.03B 31.49B | Sales 2025 * | 32.52B 4.5B 35.18B | Capitalization | 49.33B 6.83B 53.36B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.8B 387M 3.02B | Net income 2025 * | 3.19B 442M 3.45B | EV / Sales 2024 * | 1.55 x |
| Net cash position 2024 * | 4.29B 593M 4.64B | Net cash position 2025 * | 7.17B 993M 7.76B | EV / Sales 2025 * | 1.3 x |
| P/E ratio 2024 * |
17.6
x | P/E ratio 2025 * |
15.5
x | Employees | 25,806 |
| Yield 2024 * |
2.04% | Yield 2025 * |
2.35% | Free-Float | 51.81% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +5.50% | ||
| 1 week | +6.60% | ||
| Current month | +13.70% | ||
| 1 month | +7.72% | ||
| 3 months | +5.50% | ||
| 6 months | -12.54% | ||
| Current year | -11.53% |
1 week
2.81
3.10
1 month
2.293.10
Current year
2.293.49
1 year
2.294.19
3 years
2.299.69
5 years
2.2911.24
10 years
1.7411.24
| Managers | Title | Age | Since |
|---|---|---|---|
S Y Tse
CEO | Chief Executive Officer | 29 | 19-10-22 |
Ping Tse
FOU | Founder | 72 | 00-02-01 |
Chun Ling Li
DFI | Director of Finance/CFO | 53 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ping Tse
FOU | Founder | 72 | 00-02-01 |
| Director/Board Member | 60 | 04-12-31 | |
Hsin Tse
BRD | Director/Board Member | 54 | 95-07-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.40% | 0 M€ | -13.40% | - | |
| 2.02% | 4 M€ | -27.92% | ||
| 0.82% | 0 M€ | +2.32% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 3.07 | +5.50% | 87 132 813 |
| 24-05-08 | 2.91 | +1.04% | 67,230,010 |
| 24-05-07 | 2.88 | -0.35% | 37,023,090 |
| 24-05-06 | 2.89 | +0.70% | 45,016,340 |
| 24-05-03 | 2.87 | -0.35% | 30,390,300 |
Delayed Quote Hong Kong S.E., May 09, 2024 at 04:08 am EDT
More quotes
Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of cancer, ophthalmia, hepatitis, orthopedic diseases and respiratory disorders. Net sales break down by category of products as follows:
- chemical medicine products and biopharmaceutical drugs (97.6%);
- other (2.4%).
Sector
Pharmaceuticals
Calendar
2024-06-10
- Final dividend
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
2.69
CNY
Average target price
4.32
CNY
Spread / Average Target
+60.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.53% | 6.83B | |
| +32.95% | 698B | |
| +26.51% | 568B | |
| -4.97% | 358B | |
| +18.83% | 328B | |
| +3.54% | 283B | |
| +15.92% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +6.70% | 165B |
- Stock Market
- Equities
- 1177 Stock